Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 6832

BillFederalHouseIn Committee
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID–19 pandemic.
About This Bill
Committee
Latest Action · February 28, 2022
Referred to the Subcommittee on Health.
Introduced
February 25, 2022
Cosponsors (6)
0D 6R
View PDF ↗
SummaryFull TextCommentsAnnotations

Full Text

The official full text of this bill isn’t available inside AllCiv yet. Read it on Congress.gov:

A plain-language summary is on the Summary tab — you can highlight and annotate it there.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.